Retinal choroidal disease: 1
Life Sciences
Information and Communication
Nanotechnology / Materials
Manufacturing Technology
Human and Social Sciences
Energy
Environment
Tourism / Community development
Arctic Research
Social Infrastructure
Open Facilities
View All
View Detail-
Development of Novel Inhibitors Targeting the Receptor-Bound Prorenin System
Development of drugs that inhibit (pro)renin receptors involved in pathogenesis such as chronic inflammation and angiogenesis
We are working to elucidate the involvement of the renin-angiotensin system (RAS) in the pathogenesis of diabetic retinopathy and other retinal choroidal diseases, and to develop inhibitors of the (pro)renin receptor, which is upstream of the RAS, and to conduct basic research from a broad perspective.
Research
Age-related macular degeneration and diabetic retinopathy are retinal and choroidal disorders that major causes of blindness and are regarded as chronic inflammatory disorders associated with lifestyle-related diseases. However, we have yet to develop a fundamental treatment or elucidate the pathogenesis of these disorders. We have previously reported that the receptor-associated prorenin system (RAPS) regulates the molecular pathogenesis of disorders upstream of inflammation and angiogenesis in organ damage in lifestyle-related diseases. We are currently conducting basic research targeting the (pro)renin receptor, which is at the center of the receptor-associated prorenin system, with a view to drug discovery using technologies such as comprehensive small molecule compound screening and drug molecular design methods. Using animal models of diseases, we are also attempting to elucidate the function of (pro)renin receptors and to establish therapeutic strategies for early intervention in disease states while minimizing the impact on the physiological functions.
Susumu Ishida Professor
